SEncIL employs a patented spray encapsulation technique that transforms liquid drugs into solid forms without compromising their bioactive properties.

This method ensures that the resulting dry powder maintains optimal solubility and permeability, crucial for enhancing oral bioavailability.

By enabling innovators to create high-value, innovative small molecule products, SEncIL significantly reduces the risk of failure in clinical trials.​

SEncIL turns these challenges into opportunities for better treatments, faster development, and improved patient outcomes.​